Uscom (ASX:UCM) - Share price, News & Analysis

UCM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

UCM Overview

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.

Rewards

Earnings have grown 16.8% per year over the past 5 years

Risk Analysis

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$5M)

Does not have a meaningful market cap (A$20M)

Price History & Performance

Summary of all time highs, changes and price drops for Uscom
Historical stock prices
Current Share Price	AU$0.14
52 Week High	AU$0.12
52 Week Low	AU$0.19
Beta	-1.23
1 Month Change	0%
3 Month Change	-10.00%
1 Year Change	-25.00%
3 Year Change	-3.57%
5 Year Change	-46.00%
Change since IPO	-94.38%

Shareholder Returns

	UCM	AU Medical Equipment	AU Market
7D	-3.6%	0.3%	0.8%
1Y	-25.0%	-7.4%	24.4%

Return vs Industry: UCM underperformed the Australian Medical Equipment industry which returned -7.4% over the past year.

Return vs Market: UCM underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is UCM's price volatile compared to industry and market?
UCM volatility
UCM Beta	-1.23
Industry Beta	0.57
Market Beta	1

Stable Share Price: UCM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: UCM's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	35	Rob Phillips	https://www.uscom.com.au

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company provides the SpiroSonic AIR, a digital home care spirometer which feeds digital lung function signals through a phone app; and Ventitest, a digital ultrasonic ventilator testing solution for testing ventilators.

Uscom Fundamentals Summary

How do Uscom's earnings and revenue compare to its market cap?
UCM fundamental statistics
Market Cap	AU$20.36m
Earnings (TTM)	-AU$924.24k
Revenue (TTM)	AU$4.55m

4.6x

P/S Ratio

-22.9x

P/E Ratio

Is UCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
UCM income statement (TTM)
Revenue	AU$4.55m
Cost of Revenue	AU$485.07k
Gross Profit	AU$4.07m
Expenses	AU$4.99m
Earnings	-AU$924.24k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0059
Gross Margin	89.35%
Net Profit Margin	-20.29%
Debt/Equity Ratio	0%

How did UCM perform over the long term?

See historical performance and comparison

Valuation

Is Uscom undervalued compared to its fair value and its price relative to the market?

6.87x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: UCM is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: UCM is unprofitable, so we can't compare its PE Ratio to the Australian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UCM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: UCM is overvalued based on its PB Ratio (6.9x) compared to the AU Medical Equipment industry average (4.5x).

Future Growth

How is Uscom forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.1%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Uscom performed over the past 5 years?

16.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UCM is currently unprofitable.

Growing Profit Margin: UCM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: UCM is unprofitable, but has reduced losses over the past 5 years at a rate of 16.8% per year.

Accelerating Growth: Unable to compare UCM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).

Return on Equity

High ROE: UCM has a negative Return on Equity (-30.03%), as it is currently unprofitable.

Financial Health

How is Uscom's financial position?

Financial Position Analysis

Short Term Liabilities: UCM's short term assets (A$3.5M) exceed its short term liabilities (A$948.8K).

Long Term Liabilities: UCM's short term assets (A$3.5M) exceed its long term liabilities (A$1.3M).

Debt to Equity History and Analysis

Debt Level: UCM is debt free.

Reducing Debt: UCM has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable UCM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: UCM is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 21% per year.

Dividend

What is Uscom current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate UCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UCM's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UCM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average board tenure

CEO

Rob Phillips (68 yo)

no data

Tenure

AU$685,877

Compensation

Dr. Robert Allan Phillips, also known as Rob, Ph D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Offi...

CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD514.15K) is above average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.

Board Members

Experienced Board: UCM's board of directors are considered experienced (3.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.

Data	Last Updated (UTC time)
Company Analysis	2021/10/26 07:02
End of Day Share Price	2021/10/26 00:00
Earnings	2021/06/30
Annual Earnings	2021/06/30

Market Cap

7D

1Y

Updated

Data